1.44 +0.01 (0.70%)
After hours: 4:29PM EDT
|Bid||1.44 x 1100|
|Ask||1.47 x 800|
|Day's Range||1.33 - 1.70|
|52 Week Range||0.74 - 8.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.00|
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it has entered into an asset transfer agreement with Hydra Biosciences, Inc. for the transfer of all of Hydra’s interest in certain intellectual property relating to Hydra’s CatSper ion channel target portfolio. “CatSper represents a novel target for non-hormonal contraceptives for both men and women,” said Dr. David Friend, Chief Scientific Officer of Daré Bioscience.
LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of David Friend, Ph.D., to the newly created role of Chief Scientific Officer (CSO). “We are excited to add Dr. Friend to our highly accomplished women’s health leadership team,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “I first met Dr. Friend several years ago when he was at CONRAD and am thrilled that he is now bringing to Daré his broad expertise in product development, ranging from pre-IND through Phase III and NDA submissions to the FDA.
DARE is a pre-revenue, clinical-stage company engaged in the development of novel therapeutic technologies targeting unmet needs in women’s health. In July 2017, DARE obtained worldwide rights (licensed from ADVA-Tec) to Ovaprene, the company’s lead development program. While certain features of vaginal rings (including effectiveness, reversibility and convenience of monthly use) score high in consumer surveys and studies, hormone-related side-effects (including risk of serious cardiovascular events) are an oft-cited drawback of currently available options, such as NuvaRing (etonogestrel/ethinyl estradiol).
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz, RPh, to the newly created role of Global Head of Regulatory Affairs. “Mary Jarosz is an accomplished regulatory leader that brings a highly relevant set of skills to Daré. I have had the pleasure of working with Mary at a prior company, and she has supported Daré in a consulting capacity during the last year. I am thrilled to now add her to our accomplished leadership team as an employee,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. “Ms. Jarosz has presided over regulatory affairs at both large and specialty pharmaceutical companies.
Daré Bioscience Inc’s (NASDAQ:DARE): Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The US$13.12M market-cap posted a lossRead More...
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today that President and CEO Sabrina Martucci Johnson is a finalist for the Entrepreneur Of The Year® 2018 Award in San Diego. The awards program recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Sabrina was selected as a finalist by a panel of independent judges.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today the initiation of its post-coital test (PCT) clinical trial for its lead product candidate Ovaprene®, a monthly non-hormonal contraceptive vaginal ring. “The initiation of this clinical trial is an important milestone for our company,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience, Inc. “We continue to leverage our strong position in women’s sexual and reproductive health to identify and advance true innovation capable of addressing unmet needs.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has appointed Mr. Fair to the newly created position of Chief Business Officer. Mr. Fair’s role will include business and corporate development, partnering, and strategic planning. Mr. Fair was formerly the President and COO of Evofem Inc.
Daré Bioscience, Inc. (DARE), a clinical-stage women’s biopharmaceutical company, today announced it has entered into a merger agreement with Pear Tree Pharmaceuticals, Inc., a development-stage women’s biopharmaceuticals company. Daré has entered into the above merger agreement to secure the rights, currently owned by Pear Tree, to develop PT-101, a proprietary vaginal formulation of tamoxifen, as a potential treatment for vulvar and vaginal atrophy (VVA) in patients with hormone-receptor-positive breast cancer, including estrogen receptor-positive (ER-positive) and progesterone receptor-positive (PR-positive) breast cancer.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the first $224,665 of the anticipated $1.9 million in grant funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH). The award will be applied to important clinical development efforts supporting Daré’s lead product candidate Ovaprene™, a non-hormonal, non-daily intravaginal ring being studied for pregnancy prevention. “We are reaching a critical milestone in the development of Ovaprene,” said Sabrina Martucci Johnson, President & CEO of Daré Bioscience.
NEW YORK, NY / ACCESSWIRE / April 26, 2018 / Dare Biosicence shares were exploding on Wednesday after the women's biopharma company announced that it had entered into an exclusive worldwide license agreement for Juniper Pharmaceutical's Intravaginal Ring technology platform. Shares of Arcadia didn't have as good a day as Dare yesterday as news of the FDA reviewing the company's controversial Parkinson's drug Nuplazid surfaced. Daré Bioscience, Inc. shares closed up 56.69% on Wednesday with around 29 million shares traded.
Daré Bioscience, Inc. (DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today it has secured an exclusive license to Juniper Pharmaceuticals’ intravaginal ring technology, including Juniper’s three preclinical candidates. Juniper’s novel intravaginal ring technology was developed by Dr. Robert Langer from the Massachusetts Institute of Technology and Dr. William Crowley from Massachusetts General Hospital and Harvard Medical School. “We see great potential in this promising technology with already established, compelling preclinical results and intellectual property that we believe will support further drug development,” said Sabrina Martucci Johnson, Daré’s President and Chief Executive Officer.
Stock Monitor: Dare Bioscience Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free research report on BiondVax Pharma Ltd (NASDAQ: BVXV ) (''BiondVax''). ...
NEW YORK, NY / ACCESSWIRE / April 2, 2018 / Dare Bioscience, Inc. (NASDAQ: DARE ) will be discussing their earnings results in their Q4 Earnings Call to be held on April 2, 2018 at 4:30 PM Eastern Time. ...
NEW YORK, NY / ACCESSWIRE / February 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / U.S. markets rallied on Monday, after posting its worst weekly decline in two years, as President Trump unveiled details from his long awaited $200 billion ...